ATE427355T1 - Menschliche alpha2-delta4-calciumkanal- untereinheit codierende cdna - Google Patents

Menschliche alpha2-delta4-calciumkanal- untereinheit codierende cdna

Info

Publication number
ATE427355T1
ATE427355T1 AT02728726T AT02728726T ATE427355T1 AT E427355 T1 ATE427355 T1 AT E427355T1 AT 02728726 T AT02728726 T AT 02728726T AT 02728726 T AT02728726 T AT 02728726T AT E427355 T1 ATE427355 T1 AT E427355T1
Authority
AT
Austria
Prior art keywords
calcium channel
delta4
channel subunit
subunit coding
coding cdna
Prior art date
Application number
AT02728726T
Other languages
English (en)
Inventor
Ning Qin
Ellen Codd
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE427355T1 publication Critical patent/ATE427355T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02728726T 2001-04-11 2002-04-10 Menschliche alpha2-delta4-calciumkanal- untereinheit codierende cdna ATE427355T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/833,222 US7524643B2 (en) 2001-04-11 2001-04-11 CDNA encoding the human alpha2 delta4 calcium channel subunit

Publications (1)

Publication Number Publication Date
ATE427355T1 true ATE427355T1 (de) 2009-04-15

Family

ID=25263783

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02728726T ATE427355T1 (de) 2001-04-11 2002-04-10 Menschliche alpha2-delta4-calciumkanal- untereinheit codierende cdna

Country Status (8)

Country Link
US (3) US7524643B2 (de)
EP (1) EP1427825B8 (de)
JP (1) JP2005503771A (de)
AT (1) ATE427355T1 (de)
AU (1) AU2002258760B2 (de)
DE (1) DE60231816D1 (de)
ES (1) ES2323946T3 (de)
WO (1) WO2002083847A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512971B2 (en) * 2002-12-10 2013-08-20 Echelon Biosciences, Inc. Compounds and methods of use thereof for assaying lysophospholipase D activity
CN1919868B (zh) * 2005-08-26 2011-09-21 中国科学院上海生命科学研究院 慢性神经痛相关蛋白及其基因
WO2014110628A1 (en) * 2013-01-18 2014-07-24 Itek Ventures Pty Ltd Gene and mutations thereof associated with seizure disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0424397B1 (de) * 1988-04-04 1996-06-19 The Salk Institute Biotechnology Industrial Associates, Inc. Calciumkanal-zusammensetzungen und verfahren
US5712158A (en) 1995-06-06 1998-01-27 Warner-Lambert Company Cell line for the rapid expression of functional calcium channels
CA2341351A1 (en) 1998-10-07 2000-04-13 Warner-Lambert Company Alpha-2/delta gene
WO2001008635A2 (en) 1999-07-28 2001-02-08 Human Genome Sciences, Inc. Calcium channel transport polynucleotides, polypeptides, and antibodies
US6783952B1 (en) * 1999-09-16 2004-08-31 Warner-Lambert Company Secreted soluble α2δ-2, α2δ-3 or α2δ-4 calcium channel subunit polypeptides and screening assays using same

Also Published As

Publication number Publication date
HK1065067A1 (en) 2005-02-08
EP1427825B1 (de) 2009-04-01
EP1427825A4 (de) 2005-03-16
US7524643B2 (en) 2009-04-28
JP2005503771A (ja) 2005-02-10
DE60231816D1 (de) 2009-05-14
US7157248B2 (en) 2007-01-02
EP1427825B8 (de) 2009-06-17
WO2002083847A3 (en) 2004-04-01
US7820792B2 (en) 2010-10-26
US20030166045A1 (en) 2003-09-04
US20090259022A1 (en) 2009-10-15
AU2002258760B2 (en) 2007-08-09
ES2323946T3 (es) 2009-07-28
WO2002083847A2 (en) 2002-10-24
US20030170785A1 (en) 2003-09-11
EP1427825A2 (de) 2004-06-16

Similar Documents

Publication Publication Date Title
TR200100056T2 (tr) Nörotrofik faktörler
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE60325892D1 (de) Stellungs- und verwendungsverfahren
MXPA03002218A (es) Peptidos antimicrobianos y metodos de uso.
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
EA199900355A1 (ru) Теломераза обратная тринскриптаза
MY120693A (en) Human bikunin
WO2002006316A3 (en) Alpha-msh related compounds and methods of use
ATE500323T1 (de) Subtilisin-variante
DE60140773D1 (de) Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
WO2009001260A3 (en) Cosmetic use of apolipoprotein d type proteins
ATE443076T1 (de) Von protease typ ii spaltbares peptid
WO2002050111A3 (en) Isolated laminin 10
ATE427355T1 (de) Menschliche alpha2-delta4-calciumkanal- untereinheit codierende cdna
WO2008068428A3 (fr) Utilisation cosmétique de protéines de type chitinase
WO2000000506A3 (en) Human proteins having hydrophobic domains and dnas encoding these proteins
DE69529235D1 (de) Menschliche dnase i varianten
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
DE60031390D1 (de) Nukleinsäure, die für polypeptide kodieren die eine mutt-domäne enthalten
AU4956901A (en) Novel human 7tm proteins and polynucleotides encoding the same
DE60120187D1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
WO2002036633A3 (en) Human 7tm proteins and polynucleotides encoding the same
WO2004035733A3 (en) Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof
ATE438660T1 (de) Neue menschliche g-protein gekoppelten rezeptoren und dafür kodierende polynucleotide
EP1040351A4 (de) C-terminale region des "agouti-related-transcript"-proteins (art)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties